Related Experiment Video
Updated: Aug 21, 2026
Identifying, Diagnosing, and Grading Malignant Peripheral Nerve Sheath Tumors in Genetically Engineered Mouse Models
Published on: May 17, 2024
Cross-species Study of Canine and Human Peripheral Nerve Sheath Tumors: Clinical and Molecular Perspectives
Abstract:
Malignant peripheral nerve sheath tumors (MPNSTs) are aggressive sarcomas. An obstacle to treating MPNSTs is a lack of effective systemic therapies. Although over 70% of human MPNSTs have lost or inactivated the epigenome regulator polycomb repressive complex 2 ( PRC2 ), its activity and contribution to canine PNST progression remain unclear. This study compared canine peripheral nerve sheath tumors (PNSTs) and human MPNSTs across biological and clinical features, including PRC2 activity. Immunohistochemical analysis was performed for a human tissue microarray of 54 neurofibromas and 139 MPNSTs, and 63 canine PNSTs for H3K27me3, a repressive histone mark deposited by intact PRC2, and H3K27ac, which increases globally upon H3K27me3 loss. To understand the genomic alterations present in canine PNSTs, we analyzed tumor mutation burden, copy number alteration, and transcriptomes of eight canine PNST/normal pairs. The results suggested that H3K27me3 loss and associated gain of H3K27ac epigenetically drive human and canine tumors. These findings warrant further studies to evaluate whether these epigenetic deregulations alter similar gene signatures across species.
Insights
Malignant peripheral nerve sheath tumors (MPNSTs) show loss of the epigenome regulator polycomb repressive complex 2 (PRC2). This epigenetic change drives both human and canine tumors, suggesting a shared therapeutic target.
Area of Science:
- Comparative oncology
- Epigenetics
- Cancer biology
Background:
- Malignant peripheral nerve sheath tumors (MPNSTs) are aggressive sarcomas with limited treatment options.
- Over 70% of human MPNSTs exhibit loss or inactivation of polycomb repressive complex 2 (PRC2).
- The role of PRC2 in canine peripheral nerve sheath tumors (PNSTs) is not well understood.
Purpose of the Study:
- To compare biological and clinical features of canine PNSTs and human MPNSTs.
- To investigate the activity and contribution of PRC2 in canine PNST progression.
- To identify potential shared epigenetic drivers between human and canine tumors.
Main Methods:
- Immunohistochemical analysis of H3K27me3 and H3K27ac in human (neurofibromas, MPNSTs) and canine PNSTs.
- Genomic analysis of canine PNSTs, including tumor mutation burden, copy number alterations, and transcriptomes.
- Comparative analysis of epigenetic marks and genomic alterations across species.
Main Results:
- Loss of H3K27me3 (a repressive mark by PRC2) and gain of H3K27ac were observed in both human MPNSTs and canine PNSTs.
- Genomic analyses revealed alterations in canine PNSTs.
- Epigenetic deregulation involving PRC2 appears to be a common driver in these tumors.
Conclusions:
- Epigenetic alterations, specifically H3K27me3 loss and H3K27ac gain, are implicated in driving both human and canine PNSTs.
- These findings suggest that epigenetic dysregulation is a conserved mechanism in these tumors.
- Further research is warranted to explore shared gene signatures and therapeutic strategies targeting these epigenetic changes.
More Related Videos
09:33Genetic Profiling and Genome-Scale Dropout Screening to Identify Therapeutic Targets in Mouse Models of Malignant Peripheral Nerve Sheath Tumor
Published on: August 25, 2023
09:37Defining Gene Functions in Tumorigenesis by Ex vivo Ablation of Floxed Alleles in Malignant Peripheral Nerve Sheath Tumor Cells
Published on: August 25, 2021